Stocks in Action USA: Travere Therapeutics (TVTX), Ecolab (ECL), Lattice Semiconductor (LSCC)

Travere Therapeutics (TVTX): Breakthrough in the treatment of rare kidney diseases – the company plans FDA approval for Filspari! Travere Therapeutics is approaching a significant milestone in the treatment of the rare kidney disease FSGS (Focal Segmental Glomerulosclerosis). The biotech company plans to submit a New Drug Application (NDA) to the FDA by the end of March for the expansion of its drug Filspari's indication. The decision is based on the results from Phase 2 and Phase 3 studies. FSGS is a serious condition where the filtering...